March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ...

New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout.

The phase III studies are expected to begin later in 2025. Esperion markets bempedoic acid as Nexletol and Nexlizet for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction.

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the exclusive rights to ...